Azucena EsparÃ-s-Ogando

List of Publications by Year
in descending order

38 papers	2,116 citations	218381 26 h-index	329751 37 g-index
38 all docs	38 docs citations	38 times ranked	2833 citing authors

#	Article	IF	Citations
1	Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21. Cancer Research, 2022, 82, 447-457.	0.4	16
2	Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer. Npj Precision Oncology, 2021, 5, 78.	2.3	16
3	Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 383.	3.5	62
4	Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1Râ€“MEK5â€“Erk5 Pathway. Cancer Research, 2019, 79, 2244-2256.	0.4	41
5	A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. Frontiers in Immunology, 2019, 10, 2802.	2.2	24
6	MEK5 promotes lung adenocarcinoma. European Respiratory Journal, 2019, 53, 1801327.	3.1	10
7	ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. Oncogene, 2017, 36, 1733-1744.	2.6	48
8	Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies. Oncotarget, 2016, 7, 45042-45051.	0.8	21
9	Targeting the EGF/HER Ligand-Receptor System in Cancer. Current Pharmaceutical Design, 2016, 22, 5887-5898.	0.9	51
10	The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut, 2015, 64, 1454-1465.	6.1	58
11	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene, 2014, 33, 148-156.	2.6	78
12	Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget, 2014, 5, 11308-11318.	0.8	40
13	ERK5/BMK1 Is a Novel Target of the Tumor Suppressor VHL: Implication in Clear Cell Renal Carcinoma. Neoplasia, 2013, 15, 649-IN17.	2.3	53
14	Cellular Plasticity Confers Migratory and Invasive Advantages to a Population of Glioblastoma-Initiating Cells that Infiltrate Peritumoral Tissue. Stem Cells, 2013, 31, 1075-1085.	1.4	83
15	Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor. Clinical Cancer Research, 2013, 19, 2677-2687.	3.2	45
16	Abstract 2830: Multikinase inhibition by TG02 is therapeutically effective in two forms of breast cancer. , 2012, , .		0
17	Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target. PLoS ONE, 2009, 4, e5565.	1.1	99
18	ERK2, but Not ERK1, Mediates Acquired and â€œDe novoâ€•Resistance to Imatinib Mesylate: Implication for CML Therapy. PLoS ONE, 2009, 4, e6124.	1.1	41

#	Article	IF	Citations
19	Neuregulins and Cancer. Clinical Cancer Research, 2008, 14, 3237-3241.	3.2	95
20	Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Annals of Oncology, 2008, 19, 1860-1869.	0.6	57
21	The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. Nephrology Dialysis Transplantation, 2008, 23, 3403-3411.	0.4	23
22	Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2007, 25, 2656-2663.	0.8	53
23	The Extracellular Linker of pro-Neuregulin-Î±2c Is Required for Efficient Sorting and Juxtacrine Function. Molecular Biology of the Cell, 2007, 18, 380-393.	0.9	23
24	Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cellular Signalling, 2007, 19, 1473-1487.	1.7	29
25	Multifunctional role of Erk5 in multiple myeloma. Blood, 2005, 105, 4492-4499.	0.6	82
26	Bortezomib is an efficient agent in plasma cell leukemias. International Journal of Cancer, 2005, 114, 665-667.	2.3	59
27	Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin. Cancer Research, 2005, 65, 6801-6810.	0.4	63
28	Overexpression of RasN17 Fails to Neutralize Endogenous Ras in MCF7 Breast Cancer Cells. Journal of Biochemistry, 2005, 137, 731-739.	0.9	4
29	Erk5 Participates in Neuregulin Signal Transduction and Is Constitutively Active in Breast Cancer Cells Overexpressing ErbB2. Molecular and Cellular Biology, 2002, 22, 270-285.	1.1	163
30	Extracellular Signal-regulated Kinase Phosphorylates Tumor Necrosis Factor Î±-converting Enzyme at Threonine 735: A Potential Role in Regulated Shedding. Molecular Biology of the Cell, 2002, 13, 2031-2044.	0.9	273
31	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochemical Journal, 2002, 363, 211.	1.7	43
32	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochemical Journal, 2002, 363, 211-221.	1.7	51
33	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. Biochemical Journal, 2000, 346, 359.	1.7	19
34	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. Biochemical Journal, 2000, 346, 359-367.	1.7	59
35	Differential Shedding of Transmembrane Neuregulin Isoforms by the Tumor Necrosis Factor-Î±-Converting Enzyme. Molecular and Cellular Neurosciences, 2000, 16, 631-648.	1.0	152
36	Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. European Journal of Neuroscience, 1999, 11, 1421-1430.	1.2	49

#	Article	IF	Citations
37	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. Biochemical Journal, 1999, 344, 339-348.	1.7	24
38	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. Biochemical Journal, 1999, 344, 339.	1.7	9